.jpeg)
2026-07-29 06:14:14
Hetrombopag and avatrombopag are both oral thrombopoietin receptor agonists (TPO-RAs) used to treat thrombocytopenia. This article systematically compares their mechanisms of action, approved indications, dosing regimens, and safety warnings to support informed clinical decision-making.
2026-07-29 06:08:41
Lytenava (bevacizumab-vikg) is the first ophthalmic bevacizumab formulation approved by the FDA, developed by Outlook Therapeutics for the treatment of wet age-related macular degeneration (wet AMD). It received FDA approval on July 24, 2026.
2026-07-28 05:34:00
On July 24, 2026, Outlook Therapeutics announced FDA approval of Lytenava (bevacizumab-vikg) for neovascular age-related macular degeneration (wet AMD) — the first bevacizumab formulation purpose-built for intravitreal injection.
2026-07-28 02:31:53
On July 24, 2026, the U.S. FDA approved Otsuka Pharmaceutical's extended-release capsule Simtriyo (centanafadine) for the treatment of ADHD in patients aged 6 years and older. As the first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI), this once-daily oral medication simultaneously modulates three neurotransmitter pathways, offering a new long-acting option for patients with comorbid anxiety or intolerance to traditional stimulants.
2026-07-24 07:46:29
Developed by Merck, Lipfendra (enlicitide) is the first FDA-approved oral PCSK9 inhibitor, offering a once-daily tablet that significantly reduces LDL-C levels in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
2026-07-23 06:02:51
Orforglipron (brand name Foundayo) is the first approved oral small-molecule non-peptide GLP-1 receptor agonist for long-term weight management in adults with obesity or overweight, taken once daily without food or water restrictions.
2026-07-23 05:37:53
Cabozantinib (Cabozantinib) capsules are a multi-target tyrosine kinase inhibitor approved for progressive, metastatic medullary thyroid cancer (MTC), inhibiting RET, MET, and VEGFR signaling pathways to control tumor progression.
2026-07-23 02:50:52
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor for ALK-positive advanced NSCLC with potent ALK inhibition and superior CNS penetration. This article covers its mechanism of action, therapeutic advantages, efficacy factors, and adverse effect management.
2026-07-23 02:43:41
In July 2026, the FDA approved subcutaneous isatuximab (Sarclisa) for multiple myeloma across three indications spanning newly diagnosed to relapsed/refractory disease. This article reviews pivotal trial data, recommended dosing, and key safety warnings.
2026-07-23 02:29:04
Pemigatinib is an FGFR inhibitor for FGFR2 fusion/rearrangement-positive cholangiocarcinoma. This article covers common adverse effects (hyperphosphatemia, alopecia, stomatitis), ophthalmologic monitoring requirements, and dose modification strategies for safe long-term treatment.
2026-07-23 02:21:07
Selpercatinib is a selective RET kinase inhibitor for RET fusion-positive NSCLC and RET-mutant medullary thyroid carcinoma. This guide addresses meal timing, twice-daily dosing, missed dose management, and key monitoring considerations during treatment.
2026-07-23 02:11:21
Mitotane is the cornerstone drug for adrenocortical carcinoma (ACC) treatment. This article covers initial dosing, target plasma concentration range (14–20 mg/L), monitoring frequency, and adverse effect management for safe and effective therapy.
